Companies in the News

Sana Biotechnology Announces Completion of Initial Financing

SEATTLE — Sana Biotechnology, Inc. (Sana), focused on engineering cells as medicines for patients, announced today the funding of all tranches of its initial financing, raising over $700 million. With this financing, Sana’s shareholders include ARCH Venture Partners, Flagship Pioneering, Canada Pension Plan Investment Board, Baillie Gifford, F-Prime Capital, Alaska Permanent Fund, the Public Sector Pension Investment Board, Bezos Expeditions, GV, Omega Funds, Altitude Life Science Ventures, and multiple unnamed institutional investors. “Sana is dedicated to modulating genes in cells as well as replacing damaged cells in the body,” said Steve Harr, Sana President and CEO. “The commitment from

Indigo Places #3 on CNBC’s Disruptor 50 2020 List

Founders: David Perry, Geoffrey von Maltzahn and Noubar Afeyan CEO: David Perry Launched: 2014 Headquarters: Boston Funding: $850 million Valuation: $3.5 billion Key technologies: Artificial intelligence, machine learning Industry: Agriculture, farming Previous appearances on Disruptor 50 List: 2 (No. 1 in 2019) Consumer demand for healthier, sustainable and traceable food is growing — even in the face of the coronavirus crisis. This agricultural technology start-up creates seed treatments that optimize the health of a plant in order to increase its yield. Since the beginning of the pandemic, it has launched several efforts to support growers as they make their way through a planting season

Magenta Enters Collaboration Agreement with Beam to Further Explore MGTA-117

Cambridge-based Magenta Therapeutics announced today that it has entered a non-exclusive research and clinical collaboration agreement with Beam Therapeutics. The goal is to evaluate the potential use of MGTA-117, Magenta’s novel targeted antibody drug conjugate (ADC) for the conditioning of patients with sickle cell disease and beta-thalassemia. Conditioning is necessary to prepare a patient’s body to receive edited cells. Existing conditioning regimens rely on nonspecific chemotherapy or radiation. MGTA-117 precisely targets only hematopoietic stem and progenitor cells, sparing immune cells. It has also shown high selectivity, potent efficacy, and wide safety margins. Beam has demonstrated